Omeprazole Zentiva Conseil

Omeprazole, the active ingredient in Omeprazole Zentiva Conseil, is a proton pump inhibitor presented as a strength/form for oral use. It reduces stomach acid production and is used to treat conditions such as gastro‑oesophageal reflux disease, peptic ulcer disease and Zollinger‑Ellison syndrome in adults.

GNH USA supplies Omeprazole Zentiva Conseil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazole Zentiva Conseil is a proton pump inhibitor that acts on the gastric acid secretion pathway. - Gastro‑oesophageal reflux disease (GERD): provides relief of heartburn and promotes healing of erosive esophagitis. - Peptic ulcer disease: supports ulcer healing and reduces recurrence risk. - Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with gastrin‑secreting tumors.

Adverse reactions to Omeprazole may range from mild to severe.

Common Side Effects: - Headache: mild, transient headache reported in clinical use. - Diarrhoea: loose stools occurring in a minority of patients. - Nausea: occasional feeling of stomach upset. - Abdominal pain: mild discomfort or cramping. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis linked to altered gut flora. - Severe allergic reaction: rash, itching, swelling, or anaphylaxis. - Low magnesium levels: hypomagnesemia that may cause muscle cramps or cardiac arrhythmia. - Bone fracture risk: increased incidence of hip, wrist or spine fractures with long‑term use. - Liver enzyme elevation: raised ALT/AST indicating possible hepatic stress. - Acute interstitial nephritis: kidney inflammation presenting with fever and renal dysfunction.

When using Omeprazole, consider the following safety measures: - Assess renal function: adjust use in patients with severe kidney impairment. - Review hepatic status: use cautiously in moderate to severe liver disease. - Monitor long‑term use: evaluate need for continued therapy after 12 months. - Evaluate infection risk: be aware of potential increased susceptibility to gastrointestinal infections. - Consider drug‑induced nutrient deficiencies: monitor magnesium and vitamin B12 levels during prolonged therapy. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Omeprazole can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, increasing cardiovascular event risk. - Atazanavir: decreased absorption of the antiviral, compromising HIV treatment. - Methotrexate: increased serum levels, raising toxicity potential.

Moderate Interactions (Monitor Closely): - Warfarin: possible enhancement of anticoagulant effect, requiring INR monitoring. - Digoxin: altered serum concentrations, necessitating level checks. - Phenytoin: reduced phenytoin levels, may require dose adjustment.